BIO-GENE TECHNOLOGY LTD
ASX:BGTMaterialsToday’s holders own 71.0% of what they think they own, once every option and right converts.
Share count grew 67% in 24 months; runway 2–4 quarters; 5 cash raises in 24 months
BIO-GENE TECHNOLOGY LTD's ordinary share count grew 67.2% between May 2025 and August 2026, reaching 438M shares. In the past 24 months, the company raised capital five times, for total disclosed proceeds of A$9.5M. The most recent raise was a A$3.3M Placement (with SPP) in May 2026. Options and rights on issue could convert into 179M new shares, representing 40.9% of the current share count, with the nearest expiry in October 2027. None of these options are currently in the money. At the June 2026 quarter, BIO-GENE TECHNOLOGY LTD reported A$2.2M in available cash, sufficient to cover approximately 2.8 quarters of operations based on its recent spending. There are no pending proposed securities issues.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 10 Aug 2026 | 2A · quoted issue | BGT : ORDINARY FULLY PAID | 388.1M | Appendix 2A |
| 10 Aug 2026 | 2A · quoted issue | BGT : ORDINARY FULLY PAID | 420.8M | Appendix 2A |
| 10 Aug 2026 | 2A · quoted issue | BGT : ORDINARY FULLY PAID | 401.3M | Appendix 2A |
| 10 Aug 2026 | 3G · unquoted | BGT : ORDINARY FULLY PAID | 386.1M | Appendix 3G |
| 23 June 2026 | 2A · quoted issue | BGT : ORDINARY FULLY PAID | 386.1M | Appendix 2A |
Each filing states the count for the security it names, as at its own reference date and in the units of that filing — so the newest row (388.1M) need not equal the current count above (438.1M).
Capital raises
5 cash raises in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
At $0.018 today, 0 securities are in the money (0.0% of shares on issue). At double today’s price it is 124.3M (28.4% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| — | Options | Price-triggered | $0.035 | 15 Oct 2027 | 69.2M | Filing |
| BGTAN | Options | Price-triggered | $0.034 | 15 May 2028 | 55.0M | Filing |
| BGTAM | Options | Price-triggered | $0.046 | 15 May 2030 | 55.0M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 10 Aug 2026 | Andrew Guthrie | Buy placement | 200k | 100k | — | $5k | 3Y notice |
| 10 Aug 2026 | Christopher Ramsey | Buy placement | 200k | 100k | — | $5k | 3Y notice |
| 10 Aug 2026 | Peter May | Buy placement | 200k | 100k | — | $5k | 3Y notice |
| 10 Aug 2026 | Timothy Grogan | Buy placement | 200k | 100k | — | $5k | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.